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Abstract
There is increasing evidence that breast and other cancers originate from and are maintained by a small fraction of stem/
progenitor cells with self-renewal properties. Recent molecular profiling has identified six major subtypes of breast cancer:
basal-like, ErbB2-overexpressing, normal breast epithelial-like, luminal A and B, and claudin-low subtypes. To help
understand the relationship among mammary stem/progenitor cells and breast cancer subtypes, we have recently derived
distinct hTERT-immortalized human mammary stem/progenitor cell lines: a K5
+/K19
2 type, and a K5
+/K19
+ type. Under
specific culture conditions, bipotent K5
+/K19
2 stem/progenitor cells differentiated into stable clonal populations that were
K5
2/K19
2 and exhibit self-renewal and unipotent myoepithelial differentiation potential in contrast to the parental K5
+/
K19
2 cells which are bipotent. These K5
2/K19
2 cells function as myoepithelial progenitor cells and constitutively express
markers of an epithelial to mesenchymal transition (EMT) and show high invasive and migratory abilities. In addition, these
cells express a microarray signature of claudin-low breast cancers. The EMT characteristics of an un-transformed unipotent
mammary myoepithelial progenitor cells together with claudin-low signature suggests that the claudin-low breast cancer
subtype may arise from myoepithelial lineage committed progenitors. Availability of immortal MPCs should allow a more
definitive analysis of their potential to give rise to claudin-low breast cancer subtype and facilitate biological and molecular/
biochemical studies of this disease.
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Introduction
The epithelial compartment of the mammary gland is
composed of two types of cells, luminal cells that line the ductal
tree and form the secretory epithelial cells within the alveoli of a
lactating mammary gland, and outer myoepithelial cells that
border the basal lamina separating epithelial cells from the
extracellular matrix. While differentiated myoepithelial cells
resemble smooth muscle cells, they exhibit markers of epithelial
cells, such as cytokeratins [1–3]. The relationship of luminal
epithelial cells with breast cancer has received considerable
attention as tumor cells in most human breast cancers share
features of luminal cells. In contrast, the relationship of
myoepithelial cells with oncogenesis is less clear. Certain findings
suggest that myoepithelial cells play a role in suppressing
mammary oncogenesis: i) myoepithelial cells have been shown to
secrete a number of suppressor proteins that limit cancer cell
growth and invasiveness [4,5]; ii) compared to the frequency of
human breast cancers that share features of luminal cells,
neoplasms of apparent myoepithelial origin, such as myoepithe-
lioma [6] or metaplastic tumors [7], are extremely rare.
Breast cancer is a clinically heterogeneous disease [8,9].
Previous expression profiling studies have further expanded the
concept of clinical heterogeneity and identified five major subtypes
of breast cancer: basal epithelial-like, ErbB2-overexpressing,
normal breast epithelial-like and two luminal (luminal A and B)
subtypes [9–11]. Notably, analyses of patient survival have shown
significantly different outcomes for patients belonging to various
subtypes [9,11].
It is unclear whether distinct cells of origin contribute to the
heterogeneity of breast cancer and which cell types are most
susceptible to oncogenesis [12]. The correspondence of some
breast cancer subtypes with cell types present in the normal
mammary gland (such as luminal) strongly supports the idea that
breast cancer subtypes may represent malignancies of biologically
distinct cell types. Alternatively, different subtypes of breast
cancers may arise from a common precursor based on distinct
pathways of oncogene-driven reprogramming [12].
Heterogeneity of breast cancers is closely linked to tumor
progression, metastasis and treatment failure, traits traditionally
ascribed to clonal evolution as a result of inherent genomic
instability of tumor cells and tumor-host interactions [13]. The
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with tumor heterogeneity reflecting the relative fraction of cancer
stem/progenitor cells and differences in their abilities to produce
progeny at various stages of differentiation [14].
Recent molecular analyses have added further heterogeneity to
breast cancer by identifying a new, claudin-low subtype with poor
prognosis comparable to that associated with the basal subtype
[15–17]. However, the origin of claudin-low breast cancers
remains unclear. Here, we present evidence that myoepithelial
lineage restricted K5
2/K19
2 myoepithelial progenitor cells
(MPCs) derived from bipotent K5
+/K19
2 stem/progenitor cells
share a molecular gene expression signature with claudin-low
breast cancer subtype. Furthermore, MPCs express markers of
epithelial to mesenchymal transition (EMT) and exhibit higher
capacity to migrate and invade compared to more primitive
precursors. Our analyses suggest that claudin-low breast cancer
subtype may originate from or acquire characteristics of MPCs
that exhibit EMT as an intrinsic property. The immortal MPCs
generated in this study may also be useful future cellular tools to
further characterize the biology of claudin-low breast cancer
subtype upon inducing oncogenesis.
Materials and Methods
Cell culture
The hTERT-immortalized K5
+/K19
2 and MPCs were grown
in the DFCI-1 (D) medium, as described [18,19].
Antibodies
Mouse anti-claudin-1 (sc-81796) monoclonal, anti-human K19
(sc-6278), K8 (sc-8020), a–smooth muscle actin (sc-3225), Twist
(81417), GATA-3 (sc-268) and vimentin (sc-6260) antibodies were
purchased from Santa Cruz Biotechnology. Rabbit anti-claudin-3
(34–1700) or mouse anti-claudin-4 (329400) monoclonal antibod-
ies were purchased from Invitrogen. Mouse anti-occludin
(611091), mouse anti-fibronectin (610077), MUC1 (550486), and
mouse CD29 (61047) were purchased from BD Bioscience. CD49f
(CBL458), was from Chemicon International; CD90 (Thy-1) (MS-
1013-p) from Lab Vision; and ER (VP-E613) from Vector
Laboratories. Rabbit anti-human K5 (RB-160P) was from
Covance, mouse anti-human CD10 (NCL-L-CD10-270), K5
(NCL-L-CK5), K14 (NCL-L-LL02), and K18 (NCL-C51) were
from Novocastra Laboratories. P63 ab-1(4A4), mouse, MS-1081-p
were from Neo- Marker; rabbit anti-human vimentin (clone sp20,
RM-9120-S0) from Thermo Scientific; and mouse anti-human b-
actin (AC-15) was purchased from Abcam.
Isolation of MPC cells
As described earlier, serially clonally derived K5
+/K19
2 cells
[19] were seeded at low density (300 cells/100-mm dish) in a 3D
Matrigel cultures (BD Bioscience), as described previously [20].
Cells were allowed to grow for 10 days and supplemented with
fresh medium containing 2% matrigel every two days. In this
culture system, single cells form clonal acinus structures. Single
acini were then isolated, trypsinized, and gradually expanded from
96-well to 24-well plates and finally to T-25 flask. Morphologically
distinct colonies were isolated and characterized for various
markers using western blotting to identify K5
2/K19
2 clones, as
described in results section.
Affymetrix Chip-Based Microarray Analyses
Total RNA was isolated using the Trizole reagent. A total of
200 ng of total RNA from a representative MPC clone was
reverse transcribed and cRNA generated per manufacturer’s
instructions using the Affymetrix 39 IVT Express labeling kit
(Affymetrix). Resultant cRNA probes were hybridized to the
Affymetrix human U133Plus 2 genome array per manufacture’s
suggestions and the chips were scanned using a Gene Chip 3,000
6G scanner through UNMC DNA Microarray Core Facility. The
resultant data sets were scaled using GCOS software, evaluated
with respect to quality assurance parameters to include
background, hybridization kinetics, and reverse transcription
efficiency. The complete microarray data of MPCs is submitted
to Gene Expression Omnibus (GEO) database accession number
GSE34440. The parental bipotent K5
+/K19
2 cell microarray
data (accession number GSE22580) was described previously
[19].
Western blot analysis
Cell lysates were prepared using 16 SDS sample buffer,
quantified using the BCA protein assay kit (Pierce) and subjected
to western blotting using the indicated antibodies, as described
above.
Immunofluorescence staining
Cells were grown on uncoated coverslips (for cells plated in
MEGM medium (differentiation media) or DFCI-1 medium),
fixed in 4% paraformaldehyde, permeabilized with 0.3% Triton
X-100 and blocked in 5% donkey serum. The coverslips were then
incubated with primary antibodies for 2–3 h followed by Alexa
Flour 594-conjugated donkey anti-mouse (1:1,000) antibody for
1 h. The slides were mounted and images obtained under a
fluorescence microscope (Zeiss Axioplan 2 imaging microscope,
206objective).
Migration assay
The cells were trypsinized, resuspended in growth factor
deprived DFCI-3 (D3) medium [18], and 5610
4 cells/well were
added to the top of transwell chambers with an 8 mm pore size
filter (BioCoat chambers; BD Biosciences). After 10 min, DFCI-1
medium was added to the lower chamber and incubated for 13 h.
The cells on top of the membrane (not migrated) were removed
and the migrated cells at the bottom surface of the membrane
were visualized by staining with Diff-Quik Stain Set kit (Siemens
Healthcare Diagnostics Inc.) and counted using an inverted tissue
culture microscope.
Invasion assay
The invasion assay was done as above for the migration assay
except that cells were seeded on top of Matrigel-coated chambers
(BD invasion chambers; 8 mm pore size filter; BD Biosciences).
The cells were incubated for 15 h prior to counting cells at the
bottom surface as above.
Anchorage-independent colony formation assay
2 ml of 0.7% agarose in growth medium was allowed to solidify
as the bottom layer in wells of a six-well plate, and 10
5 cells in 2 ml
of 0.3% agarose in growth medium were added as the top layer.
The images were obtained 30 days after cell seeding.
Three-dimensional (3D) Matrigel Cultures
2000 cells were mixed with 200 ml matrigel and added to a
60 ml matrigel coated well of a 24 well plate. The cells were
cultured with DFCI-1 medium. Images were acquired under a
Nikon inverted microscope after 12 days culture.
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Derivation of K5
2/K19
2 cells with myoepithelial markers
from K5
+/K19
2 stem/progenitor mammary epithelial
cells
We have recently described two types (K5
+/K19
2 or K5
+/
K19
+) of hTERT-immortalized human mammary stem/progen-
itor cell lines, both of which exhibit marker profiles of bipotent
mammary stem/progenitor cells, and demonstrate the abilities of
self-renewal as well as differentiation into luminal and myoepi-
thelial cells when cultured under appropriate culture conditions
[19]. We and others have also shown that mammary stem/
progenitor cells exhibit self-renewal and differentiation abilities
when grown in 3D Matrigel cultures [21–24]. We therefore seeded
K5
+/K19
2 bipotent progenitor cells at low density in DFCI-1
medium in Matrigel culture, manually picked individual colonies
and propagated these in regular 2D culture in DFCI-1 medium
[18,25]. We observed either tight colonies similar to the self-
renewing assemblies of parental cells, colonies in which all cells
exhibited a spindle-shaped morphology, or colonies with a mixture
of both tight epithelial cells and spindle-shaped cells (Fig. 1A).
These spindle shaped colonies are reminiscent of peripheral cells
that exhibit myoepithelial characteristics when parental cells are
cultured in the MEGM medium to induce differentiation, as we
have previously shown [19]. However, unlike differentiated
myoepithelial cells that appear in MEGM medium [19], the
clonal lines with spindle-shaped morphology continued to
proliferate in culture and could be passaged indefinitely. It is
important to mention that isolation of K5
2/K19
2 cells is not the
result of a heterogeneous population already present in parental
K5
+/K19
2 cells as published previously, we had serially cloned
K5
+/K19
2 cells from hTERT-immortalized hMECs [19].
To discern the relationship of the morphologically distinct
(spindle-shaped) cell population, we characterized these for the
expression of lineage and differentiation-related markers as
compared to their parental cells, using western blotting. Com-
pared to parental mammary stem/progenitor line, the spindle-
shaped cells showed a loss or dramatically reduced expression of
keratin (K) 5, K14, p63 and CD49f, indicating that these cells were
phenotypically distinct from the parental K5
+/K19
2 cell line
(Fig. 1B and C). Like the parental cells, the spindle shaped cells
isolated are also K19
2 (data not shown). Notably, the spindle
shaped cells continued to express CD29 (Fig. 1B) and CD44
(CD44 data not shown), both well-known mammary stem cell
markers, and maintained the weak expression of luminal markers
K8 and K18. However, compared to undetectable levels of alpha
smooth muscle actin (a-SMA, a known myoepithelial marker) in
Figure 1. Isolation of MPCs (K5
2/K19
2) cells from bipotent parental (K5
+/K19
2) cells and stem/progenitor cell markers analysis. (A)
Bipotent parental cells were seeded at low density in a 3D Matrigel cultures. Shown here are phase contrast morphologies of three colonies from 3D
cultures, when transferred to 2D cultures. (B) Western blotting of parental and MPCs using indicated antibodies. Breast cancer cell lines MDA-MB-231,
MCF-7, and Hs578T cells are used as controls. (C) Immunofluorescence staining of parental and MPCs using CD49f antibody (red), blue nuclei are
stained with DAPI.
doi:10.1371/journal.pone.0035338.g001
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detectable a-SMA signals (Fig. 1B). Co-expression of stem cell
(CD29 and CD44), luminal (K8, K18) and myoepithelial (a-SMA)
markers suggests that the spindle-shaped progeny of the parental
K5
+/K19
2 line represent a progenitor population. We designated
this population of cells K5
2/K19
2 to distinguish them from the
K5
+/K19
2 or K5
+/K19
+ bipotent stem/progenitor cells we have
previously identified and published [19]. Significantly, in multiple
experiments we could reproducibly derive the spindle-shaped
K5
2/K19
2 population from K5
+/K19
2 parental lines, whereas
we could not isolate such cells from K5
+/K19
+ lines, even though
both types of stem/progenitors are capable of differentiating into
luminal as well as myoepithelial lineages when cultured in MEGM
medium [19].
K5
2/K19
2 cells indefinitely maintain self-renewal and
exhibit unipotent myoepithelial differentiation upon
induction
To test the bipotent differentiation potential of K5
2/K19
2
hMEC population suggested by their stable co-expression of stem,
luminal and myoepithelial cell markers we cultured these in the
MEGM differentiation medium. Under these conditions, the
spindle-shaped cells continued to grow, suggesting their ability to
self-renew. Western blot comparison of parental, K5
2/K19
2 and
differentiated myoepithelial cells (derived from K5
2/K19
2)
showed a marked up-regulation of the myoepithelial cell markers
CD10 and a-SMA in differentiated myoepithelial cells (Fig. 2A).
Immunofluorescence analyses of Thy-1, another myoepithelial
marker showed an increase in the intensity of staining; the increase
was seen in a variable proportion of cells, apparently reflecting
more advanced myoepithelial differentiation of some cells (Fig. 2B).
As expected, the bipotent parental cells did not show expression
for myoepithelial differentiation markers (Fig. 2A and B). In
contrast to the readily detectable myoepithelial differentiation,
when K5
2/K19
2 cells were plated in differentiation medium, we
found no evidence of luminal differentiation in repeated
experiments. Based on the apparent unipotent differentiation
ability of K5
2/K19
2 cells to undergo further transition towards
full myoepithelial differentiation and their failure to undergo
luminal differentiation, we suggest that these cells represent
myoepithelial progenitor cells (MPCs).
Figure 2. Comparison of myoepithelial markers in MPCs and terminally differentiated myoepithelial cells. (A) Western blotting of
lysates prepared from bipotent parental cells, MPC, and differentiated myoepithelial cells, using antibodies against the myoepithelial markers CD10
and a-SMA. (B) Immunofluorescence staining of bipotent parental cells, MPC, and differentiated myoepithelial cells using the myoepithelial marker
Thy-1 (red), blue nuclei are stained with DAPI.
doi:10.1371/journal.pone.0035338.g002
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Based on the spindle shaped morphology of MPCs, we
hypothesized that they may possess characteristics of EMT cells.
To test this idea, we used western blotting to assess the expression
of known EMT markers. In contrast to the parental bipotent cells,
the MPCs showed loss of expression of epithelial makers E-
cadherin and P-cadherin and dramatic increase in the level of
vimentin expression together with de novo high level expression of
ZEB1, Twist1, N-cadherin and fibronectin, all markers of
mesenchymal cells (Fig. 3). As controls, a non-invasive luminal
breast cancer cell line MCF-7 express E-cadherin but no
mesenchymal markers, whereas MDA-MB-231 and Hs578T two
known invasive breast cancer cell lines lack E- and P-Cadherin
expression but express some of the mesenchymal markers tested
(Fig. 3). These results clearly indicate that MPCs express EMT
markers compared to their parental cells.
MPCs express a molecular signature of claudin-low
subtype of breast cancer
Evidence presented above demonstrates that MPCs are distinct
from other stem/progenitor cell types. To further characterize
their distinctive features, we performed microarray analysis of
MPCs with their parental bipotent cell type. Using the published
claudin-low gene expression signature [15,17] we observed that
MPCs exhibit the same differential gene expression patterns as the
claudin-low subtype of breast cancer (Table 1). We used western
blot and immunofluorescence analyses to verify the expression of a
number of genes associated with the claudin-low signature. These
analyses confirmed the loss of expression of claudins 1 and 4, and
occludin in MPC as compared to parental bipotent cells (Fig. 4A).
In addition, both parental bipotent and MPCs do not express
proteins such as, claudin 3, ER, ESA, MUC1 and GATA3
(Fig. 4A), that are known signature of claudin-low breast cancers.
Furthermore, as shown above MPCs lack expression of CD24
(Fig. 4B), K5, K14 (Fig. 1B), CD49f (Fig. 1C) and E-cadherin
(Fig. 3), further reinforcing their signature of claudin-low breast
cancers. Taken together the expression profile mentioned above,
and an increase in expression of CD10 (Fig. 2A), Thy-1 (Fig. 2B),
ZEB1, Twist1 and Vimentin (Fig. 3), underscores that MPCs share
a molecular signature with claudin-low subtype of breast cancer.
Taken together, these results demonstrate that MPCs have a
signature of the claudin-low subtype of breast cancers.
MPCs exhibit higher migration and invasion
Given the expression of markers of EMT in MPCs, and the
known association of EMT with increased migration/invasion
abilities of cells [26,27], we compared the parental bipotent cells
with MPCs for migration and invasion using transwell chambers.
Indeed, the MPCs exhibit substantially elevated levels of cell
migration (Fig. 5A) and invasion through Matrigel (Fig. 5B) when
compared with parental bipotent cells.
MPCs form branching structures instead of acini or ductal
structures in 3D cultures
As we and others have shown, the mammary stem/progenitor
cells form acinar structure in 3D Matrigel cultures, consistent with
establishment of polarized epithelial cell layers [21,24]. EMT is
associated with a loss of polarity and loss of acinar/ductal
formation on Matrigel [28]. We therefore compared the parental
bipotent cells and the MPCs ability to form structures in 3D
Matrigel culture. Notably, while the parental cells expectedly
formed acinar structures, MPCs formed branching structures
(Fig. 5C) consistent with their increased migratory and invasive
properties. While the MPCs exhibit EMT and loss of polarized
acinar growth in 3D culture, neither their parental cells nor the
MPCs exhibit anchorage-independent growth, a characteristic of
oncogenically transformed cells, when cultured on soft agar
(Fig. 5D).
Discussion
Luminal and myoepithelial components of the mammary gland
share their developmental origin yet very little is known about
molecular pathways involved in the generation of myoepithelial
cells and their precise relation to human breast cancer remains
relatively unclear and under-explored. Here, we describe the
isolation of immortal human mammary progenitor cells that stably
express characteristics consistent with myoepithelial progenitor
cells (MPCs). Molecular and functional characterization of the
MPCs we established here demonstrate that they exhibit EMT
characteristics and molecular signatures shared with claudin-low
breast cancers raising the possibility that claudin-low breast cancer
subtype arises from myoepithelial progenitors.
Previously we established human mammary epithelial stem/
progenitor cell lines with K5
+/K19
+ or K5
+/K19
2 phenotype
both of which exhibit self-renewal potential and the ability to
differentiate into luminal as well as myoepithelial progeny [19]. In
this study, we demonstrate that K5
+/K19
2 cell type differentiate
to K5
2/K19
2 cells that exhibit myoepithelial lineage character-
istics. Co-expression of luminal, myoepithelial and stem cell
markers strongly suggested that these cells represented progenitor
cells rather than terminally-differentiated myoepithelial cells. As
MPC were derived from clonal bipotent parental cells, this
eliminated the possibility of heterogeneity within the parental
population. While parental cells yield both luminal and myoepi-
Figure 3. Western blotting of MPCs using EMT markers. Cell
lysates from exponentially proliferating bipotent parental and MPCs
were analyzed for expression of indicated EMT markers using specific
antibodies. Breast cancer cell lines MDA-MB-231, MCF-7, and Hs578T
were used as controls.
doi:10.1371/journal.pone.0035338.g003
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K5
2/K19
2cells only yielded further differentiation along the
myoepithelial lineage with upregulation of myoepithelial markers.
Thus, we conclude that stable K5
2/K19
2 progeny from the K5
+/
K19
2 mammary stem/progenitors represents myoepithelial pro-
genitor cells (MPCs).
The derivation of MPC from bipotent K5
+/K19
2 cells, but our
inability to obtain such cells from bipotent K5
+/K19
+ cells suggest
that we may not have yet identified the appropriate in vitro
conditions for generating MPCs from K5
+/K19
+cells in matrigel
or that K5
+/K19
+cells lack the ability to differentiate into MPCs
under these conditions. This important distinction for lineage
relationships and committed states of human mammary stem and
progenitor cells will require detailed future studies.
We observed that MPCs exhibit markers of EMT and showed
elevated levels of cell migration and invasion compared to their
parental cells. The linkage of EMT in mammary epithelial cells
with elevated cell migration and invasion has been examined
primarily in the context of cancer cells due to the potential
importance of these traits in tumor metastasis [26,27] and radio-
and chemo-resistance [29]. However, recent studies have begun to
link EMT to mammary epithelial stem cells [30]. In fact, ectopic
expression of genes that promote EMT in mammary epithelial
cells without EMT has been shown to promote traits associated
with mammary stem cells [30]. Given our findings that two distinct
types of human mammary stem/progenitors with bipotent
differentiation capabilities (K5
+/K19
2 and K5
+/K19
+) do not
exhibit molecular or phenotypic evidence of EMT but a unipotent
MPC derived from one of these (K5
+/K19
2) exhibits this trait, the
linkage of EMT with mammary stem cell behavior should be
interpreted with caution. It is possible that EMT is either a
transitional feature of mammary stem cells or a feature of certain
committed progenitors, such as MPCs, as we show here.
Consistent with this idea, a recent study showed that the
EpCAM
pos/CD49f
high subpopulation of cells within non-tumori-
genic basal mammary epithelial cell lines (MCF10A and
MCF12A) spontaneously attained mesenchymal-like features
through EMT and do not exhibit stem cell properties [31].
Importantly, recent studies have shown that EMT is a feature of
the claudin-low subtypes of breast cancers which is associated with
poor prognosis and resistance to therapy [15]. Our findings that
MPCs exhibit an EMT phenotype, and share a molecular
signature with claudin-low breast cancers suggests the possibility
that the claudin-low subtype may originate from MPCs or from a
rewiring of differentiated mammary epithelial cells to a MPC-like
state. In support of this theory, a recent report has shown that
Table 1. Comparison of claudin-low gene signature from microarray analysis of parental bipotent cells and MPCs.
Gene Symbol Gene Title Parental mas5_Signal MPCs mas5_Signal
CLDN1 claudin 1 500.5 1.9
CLDN3 claudin 3 20.1 20.4
CLDN4 claudin 4 616.9 29.6
CLDN7 claudin 7 881 45.6
CDH1 cadherin 1, type 1, E-cadherin (epithelial) 19103.8 2.5
OCLN occludin 354.6 49.9
VIM vimentin 15990.8 28292.7
ZEB1 zinc finger E-box binding homeobox 1 43.2 5205.2
ZEB2 zinc finger E-box binding homeobox 2 20 528.2
TWIST1 twist homolog 1 (Drosophila) 357.8 9140.2
TWIST2 twist homolog 2 (Drosophila) 714.9 2617.4
KRT5 keratin 5 18257.2 499.1
KRT14 keratin 14 49967.4 2021.5
KRT17 keratin 17 29653 936.2
KRT18 keratin 18 8268.7 5619.3
KRT19 keratin 19 4.4 1.3
ESR1 estrogen receptor 1 12 55.3
PGR progesterone receptor 8.5 4.9
GATA3 GATA binding protein 3 277 13.6
ERBB2 epidermal growth factor receptor 2 44.6 48.4
CD44 CD44 molecule (Indian blood group) 6799.4 2800.3
CD24 CD24 molecule 5808.7 10.7
MME(CD10) membrane metallo-endopeptidase 966.7 8419.2
ITGA6(CD49f) integrin, alpha 6 3766 329.9
ITGB1(CD29) integrin, beta 1 32483.1 29343.6
MUC1 mucin 1, cell surface associated 135.8 143.9
THY1 Thy-1 cell surface antigen 8.4 1403.8
Shown here are MAS5 normalized expression signals of claudin-low signature genes from our microarray analysis upon differentiation of bipotent parental (K5
+/K19
2)
cells to unipotent MPCs (K5
2/K19
2).
doi:10.1371/journal.pone.0035338.t001
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PLoS ONE | www.plosone.org 6 April 2012 | Volume 7 | Issue 4 | e35338Figure 4. Western blot and immunofluorescence analysis of parental bipotent cells and MPCs using various markers from the
signature of claudin-low breast cancer subtype. (A) Western blot analysis of cell lysates from exponentially proliferating bipotent cells and
MPCs were analyzed for expression of indicated markers using specific antibodies. Breast cancer cell lines MDA-MB-231, MCF-7, and Hs578T were
used as controls. (B) Immunofluorescence staining using CD24 antibody (red), nuclei (blue) represent DAPI staining.
doi:10.1371/journal.pone.0035338.g004
Figure 5. Comparison of parental bipotent cells and MPCs for invasion, migration, anchorage independence and 3D proliferation in
matrigel. (A) Migration assay using transwell chambers were performed on exponentially proliferating indicated cells. Shown here is a bar diagram
of the number of cells that migrated in both cell types. The data represents the mean
+/2 standard deviation (SD) of three experiments done in six
replicates. (B) Invasion assay were performed with indicated cells using matrigel coated transwell chambers. Shown here is a bar diagram of number
of cells that invaded in both cell types. The data represent mean
+/2 SD of three experiments done in six replicates. (C) 3D matrigel culture. Shown
here are phase contrast pictures at day12 using an inverted microscope. (D) Exponentially proliferating cells were analyzed for anchorage
independence by soft agar assay. Shown here are images of colonies after 30 days, using inverted microscope.
doi:10.1371/journal.pone.0035338.g005
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and K-ras results in metaplastic carcinomas resembling claudin-
low tumors [7]. Regardless of the mechanisms, the potential
linkage of claudin-low breast cancers with MPCs should help
rethink the role of myoepithelial lineage in breast cancer. While
myoepithelial cells have been suggested to protect mammary
tumorigenesis [4,5,32], they are known to contribute to the
synthesis and remodeling of the basal lamina and the basement
membrane, and are known to exert paracrine effects on secretary
epithelial cells [32]. Consistent with these functions, several lines of
evidence suggest that myoepithelial cells regulate the progression
of ductal carcinoma in situ (DCIS) to invasive breast cancer [32].
Notably, myoepithelial tumors such as myoepithelioma [33] and
metaplastic carcinomas [7] are rare but aggressive. These studies
underscore the importance of further research in understanding
the origin and contribution of myoepithelial cells to breast cancers.
In conclusion, we have isolated a MPC population from K5
+/
K19
2 bipotent stem/progenitor cells that exhibits unipotent
myoepithelial lineage-specific differentiation. Importantly, these
cells exhibit intrinsic EMT characteristics and elevated cell
migration and invasion. Significantly, MPCs share a molecular
signature with claudin-low breast cancers. Together, these findings
suggest that MPC with EMT characteristics may represent a
precursor cell type for claudin-low breast cancer.
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